Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia

Neurology: Neuroimmunology and NeuroInflammation

Volumn 3, Issue 2, 2016, Pages

  Miskin, Dhanashri P ^a   Chalkias, Spyridon G ^a   Dang, Xin ^a   Bord, Evelyn ^a   Batson, Stephanie ^a   Koralnik, Igor J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 7;

AGED; ARTERIAL SPIN LABELING; ARTICLE; BRAIN BIOPSY; CASE REPORT; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG RESPONSE; GLIOSIS; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MACROPHAGE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VERY ELDERLY;

EID: 85006313031     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000213     Document Type: Article

References (12)

1. Gheuens S, Wuthrich C, Koralnik IJ. Progressive multifocal leukoencephalopathy: why gray and white matter. Annu Rev Pathol 2013;8:189-215.
2. Delgado-Alvarado M, Sedano MJ, Gonzalez-Quintanilla V, de Lucas EM, Polo JM, Berciano J. Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia. J Neurol Sci 2013;327:75-79.
3. Zonios DI, Falloon J, Bennett JE, et al. Idiopathic CD41 lymphocytopenia: natural history and prognostic factors. Blood 2008;112:287-294.
4. Patel A, Patel J, Ikwuagwu J. Treatment of progressive multifocal leukoencephalopathy and idiopathic CD41 lymphocytopenia. J Antimicrob Chemother 2010;65: 2489-2492.
5. Gheuens S, Bord E, Kesari S, et al. Role of CD41 and CD81 T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 2011;85:7256-7263.
6. Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11:330-342.
7. Alstadhaug KB, Croughs T, Henriksen S, et al. Treatment of progressive multifocal leukoencephalopathy with interleukin 1. JAMA Neurol 2014;71:1030-1035.
8. Sospedra M, Schippling S, Yousef S, et al. Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1. Clin Infect Dis 2014;59:1588-1592.
9. Gasnault J, de Goer de Herve MG, Michot JM, et al. Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy. Open Forum Infect Dis 2014;1: ofu074.
10. Gheuens S, Ngo L, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ. Metabolic profile of PML lesions in patients with and without IRIS: an observational study. Neurology 2012;79:1041-1048.
11. Khoury MN, Gheuens S, Ngo L, Wang X, Alsop DC, Koralnik IJ. Hyperperfusion in progressive multifocal leukoencephalopathy is associated with disease progression and absence of immune reconstitution inflammatory syndrome. Brain 2013;136:3441-3450.
12. Marzocchetti A, Tompkins T, Clifford DB, et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009;73:1551-1558.